Nkarta Inc (NKTX) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
Nkarta Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Investment, Quarterly Results, Trends, Rankings, Statistics
What is Nkarta Inc's ROI in the second quarter of 2026?
Nkarta Inc recorded a cumulative net loss of $-117 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -32.4%.
Within the Healthcare sector 140 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 2917 to 3381.
Nkarta Strengthens Leadership Team with New President and Chief Medical Officer July 16, 2024 - Nkarta, Inc. (Nasdaq: NKTX), a pioneering biopharmaceutical company specializing in engineered natural killer (NK) cell therapies, has announced significant changes to its leadership team. The company welcomes the appointment of Dr. Nadir Mahmood as President, who will share executive leadership responsibilities with Chief Executive Officer Paul J. Hastings. Additionally, Nkarta has expanded the role of Dr. David R. Shook, appointing him as Chief Medical Officer and Head of Research and Development. These changes reflect Nkarta s commitment to advancing its innovative cell therapy pipeline and driving growth in the biopharmaceutical industry. Dr. Nadir Mahmood, a distinguished leader in the biopharmaceutical and healthcare sectors, brings a wealth of experience to Nkarta. Having held various executive positions in prominent organizations, Dr. Mahmood s expertise lies in driving strategic growth and spearheading successful commercialization efforts. His appointment as President signifies the company s focus on expanding its market reach, capitalizing on emerging opportunities, and fostering collaborations to accelerate the development and accessibility of NK cell therapies.
Nkarta s Recent Underwritten Offering and Financial Performance Reflects Volatility in Biopharmaceutical Sector SOUTH SAN FRANCISCO, Calif., March 25, 2024 - Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company specializing in the development of engineered natural killer (NK) cell therapies, recently announced the pricing of an underwritten offering, aiming to raise $240 million. However, this news comes amid concerns regarding the company s financial performance, particularly with a cumulative net loss of $122 million recorded during the 12 months ending in the third quarter of 2023. This indicates a negative return on investment (ROI) of -29.38%, highlighting potential challenges for investors. The underwritten offering comprises 21,010,000 shares of Nkarta s common stock, priced at $10.00 per share, along with pre-funded warrants enabling the purchase of 3,000,031 shares of common stock. The pre-funded warrants are being sold at $9.9999 per warrant, which reflects the offering price for the common stock less the $0.0001 per share exercise price.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
